<DOC>
	<DOCNO>NCT00317941</DOCNO>
	<brief_summary>The purpose study compare injection site reaction injection site pain subcutaneous administration either Betaferon 250µg Rebif 44µg use different autoinjector .</brief_summary>
	<brief_title>Safety Study Relapsing-remitting Multiple Sclerosis ( RRMS ) Patients Receiving Betaferon Rebif</brief_title>
	<detailed_description>Original French title study : Etude de phase IV , multicentrique , randomisée , ouverte , comparant le réactions et la douleur aux sit d'injection après administration sous-cutanée d'interféron β-1b ( Betaferon® ) ou interféron β-1a ( Rebif® ) pendant la période de trois mois d'initiation de la thérapie chez de patient atteints d'une forme récurrente/rémittente de sclérose en plaque . The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer HealthCare AG , Germany . Bayer HealthCare AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Males female Age &gt; = 18 year old Patients first demyelinate event suggestive MS ( Betaferon ) well patient definite diagnosis RRMS ( Betaferon et Rebif ) First justify prescription one interferon beta subcutaneous route ( describe Summary Product Characteristics [ SmPC ] Betaferon Rebif ) Females childbearing potential must agree practice adequate contraceptive method duration study ( applicable men ) Patient follow comply study procedures trial protocol Laboratory evaluation ( i.e. , evaluation hepatic enzyme gammaGT , full blood count differential white blood cell count [ WBC ] ) must available result must normal . Written informed consent Any contraindication prescription Betaferon Rebif , describe SmPC product : Pregnancy lactation Known hypersensitivity natural recombinant interferon beta , mannitol , human albumin excipients use History severe depression suicide attempt current suicidal ideation . Patient decompensated liver disease Epilepsy adequately control treatment Patient previously include study . Patient previously treat subcutaneous route either Betaferon Rebif . Participation clinical trial within past 30 day involve investigational drug intake . Medical , psychiatric condition compromise patient 's ability understand patient information , give informed consent , comply trial protocol complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
</DOC>